Payment overview · 2025
General Payments
$399.93
23 reported records · 9 companies
Healthcare provider profile · identity verified
Larry Kramer, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SALISBURY, MD · NPI 1134118664
Verified facts
What the public records show
CMS Open Payments records show Larry Kramer, CRNP received $399.93 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.94 | 18.5% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $71.24 | 17.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.12 | 12.3% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $40.21 | 10.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.73 | 9.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.66 | 9.2% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35.12 | 8.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.69 | 8.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.22 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $399.93 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $49.64 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $40.21 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.20 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.20 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.73 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $36.66 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $35.12 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.74 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.69 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.69 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.76 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.76 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 112 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 569 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 286 | 71 |
| Alprazolam | Alprazolam | 216 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 205 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 188 | 61 |
| Gabapentin | Gabapentin | 187 | 46 |
| Potassium Chloride | Potassium Chloride | 179 | 42 |
| Omeprazole | Omeprazole | 178 | 45 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 168 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 32 |
| Famotidine | Famotidine | 128 | 30 |
| Lisinopril | Lisinopril | 126 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 31 |
| Furosemide | Furosemide | 119 | 33 |
| Metformin Hcl Er | Metformin Hcl | 119 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 113 | 33 |
| Ozempic | Semaglutide | 112 | 17 |
| Montelukast Sodium | Montelukast Sodium | 110 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 107 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 104 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 33 |
| Carvedilol | Carvedilol | 97 | 29 |
| Glipizide Er | Glipizide | 97 | 31 |
| Losartan Potassium | Losartan Potassium | 91 | 19 |
| Amoxicillin | Amoxicillin | 90 | 46 |
| Meloxicam | Meloxicam | 84 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 83 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 20 |
| Ibuprofen | Ibuprofen | 69 | 24 |
| Jardiance | Empagliflozin | 69 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | suppressed |
| Allopurinol | Allopurinol | 67 | 16 |
| Simvastatin | Simvastatin | 67 | 23 |
| Naproxen | Naproxen | 66 | 27 |
| Ventolin Hfa | Albuterol Sulfate | 66 | 14 |
| Clonidine Hcl | Clonidine Hcl | 65 | 13 |
| Baclofen | Baclofen | 62 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 19 |
| Trazodone Hcl | Trazodone Hcl | 61 | 11 |
| Atenolol | Atenolol | 56 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 14 |
| Ezetimibe | Ezetimibe | 51 | 20 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 11 |
| Glipizide | Glipizide | 48 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 41 | 13 |
| Mirtazapine | Mirtazapine | 40 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | suppressed |
| Nifedipine Er | Nifedipine | 36 | 12 |
| Topiramate | Topiramate | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Eliquis | Apixaban | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 27 |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 28 |
| Prednisone | Prednisone | 32 | 26 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Metformin Hcl | Metformin Hcl | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 24 | suppressed |
| Azithromycin | Azithromycin | 24 | 18 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Alogliptin-Metformin | Alogliptin Benz/Metformin Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Diazepam | Diazepam | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 11 |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Paliperidone Er | Paliperidone | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Trospium Chloride | Trospium Chloride | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Xtampza Er | Oxycodone Myristate | 14 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $399.93 · 23 records | ABBVIE INC. | AIRSUPRA, BREZTRI, FREESTYLE LIBRE 3, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error